Impact of sugammadex on neuromuscular blocking agents use: A multicentric, pharmaco-epidemiologic study in French university hospitals and military hospitals

Autor: Beny, K., Piriou, V., Dussart, C., Henaine, R., Aulagner, Gilles, Armoiry, Xavier, Pharmacoepidemiology, Experts NMBA

Publikováno v: Annales Françaises d'Anesthésie et de Réanimation
Annales Françaises d'Anesthésie et de Réanimation, Elsevier Masson, 2013, 32 (12), pp.838-843. 〈10.1016/j.annfar.2013.08.004〉
Annales Françaises d'Anesthésie et de Réanimation, Elsevier Masson, 2013, 32 (12), pp.838-843. ⟨10.1016/j.annfar.2013.08.004⟩

International audience; Introduction. - Seven Neuromuscular Blocking Agents (NMBA) are commercialized in France. Four of them have an intermediate duration of action. Sugammadex required the use of NMBA slightly employed in clinical practice in Franc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::2364975091931d535c294d087cd5e249
https://hal.archives-ouvertes.fr/hal-01814463